<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04472455</url>
  </required_header>
  <id_info>
    <org_study_id>2017-347</org_study_id>
    <nct_id>NCT04472455</nct_id>
  </id_info>
  <brief_title>Mobile High-Resolution Microendoscopy (mHRME) for the Detection of Cervical Dysplasia in El Salvador</brief_title>
  <official_title>Mobile High-Resolution Microendoscopy (mHRME) for the Detection of Cervical Dysplasia in El Salvador</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Marsh Rice University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Basic Health International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>William Marsh Rice University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the performance of the mHRME in a study of 3,000 women in San Salvador to assess
      whether mHRME imaging improves specificity of screening by VIA or HPV DNA without reducing
      sensitivity for cervical precancer and cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective cohort study. Eligibility is open to women 30-49 years old, who are not
      pregnant, have an intact cervix, and no history of cervical cancer.

      Visit 1:

      Patients will enroll at the screening clinic of the Instituto del Cáncer de El Salvador (El
      Salvador Cancer Institute, ICES). An informed consent will be obtained. They will be given a
      urine pregnancy test; if negative, two cervical samples will be collected. The first sample
      will be used to screen for HPV DNA. New technologies to screen for oncoproteins and HPV will
      be applied to the second sample. 3-5% acetic acid will also be applied to the cervix to
      perform the VIA. Images of the cervix will be taken and any personally identifiable
      information removed.

      Visit 2:

      All women with a positive VIA or HPV test will undergo additional evaluation. In addition,
      10% of women in the double negative group (VIA-/HPV-) will be randomly selected for
      evaluation. This evaluation includes: Urine pregnancy test, VIA, colposcopy, Lugol's solution
      application, and a HRME. 3-5% acetic acid will be applied to the cervix to perform the VIA.
      Proflavine and Lugol's solution (2-5%) will be applied and once again the health care
      provider will record their impression for each of the abnormal lesions. Cervical images will
      be taken. Then, 0.01% proflavine will be topically applied to the cervix for 1 minute. Images
      will be obtained using the mHRME system of a visually normal site and then of all lesions
      identified by VIA, colposcopy, and/or Lugol's solution. If no lesions are identified by VIA,
      colposcopy, and/or Lugol's solution, mHRME images will be taken of each quadrant. Samples of
      abnormal areas identified by VIA, colposcopy, Lugol's solution, and/or mHRME will be
      collected for biopsy and ECC purposes. If the evaluation shows no abnormalities, a random
      sample will be collected from the squamocolumnar junction and an ECC will be performed (only
      if the patient is HPV positive). Two expert pathologists will review and classify the
      samples. All research results will be unbeknownst to them. They will use the following
      classification system: normal, CIN 1, CIN 2, CIN 3, AIS, or cancer, per standard criteria.
      Discrepant results are resolved by a third expert pathologist, with the final result being
      based on 2/3 agreement. If all three pathologists arrive at different diagnoses, all three
      will meet in person to review to reach a consensus diagnosis. Women with CIN 2+ will undergo
      an excision or cryotherapy, according to the treatment standard. Patients diagnosed with
      invasive cancer will be referred to gynecology/oncology.

      The sensitivity, specificity, positive predictive value, and negative predictive value for
      each screening and triage method will be compared using histopathology as the gold standard.
      These results will enable us to compare the total number of women that could have received
      adequate and inadequate treatment based on five of the most predominant clinical scenarios:
      VIA alone, VIA/mHRME triage, HPV test alone, HPV/VIA triage, and HPV/mHRME triage.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">April 2, 2019</completion_date>
  <primary_completion_date type="Actual">April 2, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of mHRME to detect CIN2+</measure>
    <time_frame>1-2 days</time_frame>
    <description>Calculate the sensitivity, specificity, positive predictive value, and negative predictive value of mHRME to detect CIN2+.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of different screening and triage strategies to detect CIN2+</measure>
    <time_frame>1-2 days</time_frame>
    <description>Compare the sensitivities and specificities of the following theoretical strategies to detect CIN2+: VIA alone, VIA/mHRME triage, HPV test alone, HPV/VIA triage, and HPV/mHRME triage.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">1827</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Screen Negative Group</arm_group_label>
    <description>All women who screen negative at Visit 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Screen Positive Group</arm_group_label>
    <description>All women who screened positive at Visit 1 and were invited to Visit 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10% Of Screen Negative Group</arm_group_label>
    <description>10% of women who screened negative at Visit 1 and were invited to Visit 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HRME</intervention_name>
    <arm_group_label>10% Of Screen Negative Group</arm_group_label>
    <arm_group_label>Screen Negative Group</arm_group_label>
    <arm_group_label>Screen Positive Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cervical swab samples are collected to test for HPV DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This is a prospective cohort study. Eligibility is open to women 30-49 years old, who are
        not pregn ant, have an intact cervix and no history of cervical cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women who are between the ages of 30 and 49 years of age

          2. All women must have a negative urine or serum pregnancy test prior to any study
             procedure (within 7 days)

          3. Intact cervix (patients who have undergone previous LEEP, cone and/ or cryotherapy are
             not eligible)

          4. No history of invasive cervical cancer

          5. Able and willing to provide informed consent

        Exclusion Criteria:

          1. Women &lt; 30 years of age or over 49 years of age

          2. Women who have undergone a hysterectomy with removal of the cervix

          3. Women who have had a previous LEEP, Cold knife cone and/or cryotherapy

          4. Women who are pregnant or breastfeeding

          5. Women with a history of invasive cervical cancer

          6. Unable or unwilling to provide informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauricio Maza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Basic Health International</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rebecca Richards-Kortum, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Marsh Rice University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen Schmeler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <reference>
    <citation>Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. 1941. Arch Pathol Lab Med. 1997 Mar;121(3):211-24.</citation>
    <PMID>9111103</PMID>
  </reference>
  <reference>
    <citation>Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.</citation>
    <PMID>21296855</PMID>
  </reference>
  <reference>
    <citation>Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep;189(1):12-9.</citation>
    <PMID>10451482</PMID>
  </reference>
  <reference>
    <citation>FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007 May 10;356(19):1915-27.</citation>
    <PMID>17494925</PMID>
  </reference>
  <reference>
    <citation>Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009 Jul 25;374(9686):301-14. doi: 10.1016/S0140-6736(09)61248-4. Epub 2009 Jul 6. Erratum in: Lancet. 2010 Sep 25;376(9746):1054.</citation>
    <PMID>19586656</PMID>
  </reference>
  <reference>
    <citation>Chou B, Krill LS, Horton BB, Barat CE, Trimble CL. Disparities in human papillomavirus vaccine completion among vaccine initiators. Obstet Gynecol. 2011 Jul;118(1):14-20. doi: 10.1097/AOG.0b013e318220ebf3.</citation>
    <PMID>21691158</PMID>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years--United States, 2008. MMWR Morb Mortal Wkly Rep. 2009 Sep 18;58(36):997-1001.</citation>
    <PMID>19763075</PMID>
  </reference>
  <reference>
    <citation>Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, Fayette JM, Cherian J. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet. 2007 Aug 4;370(9585):398-406.</citation>
    <PMID>17679017</PMID>
  </reference>
  <reference>
    <citation>Visual inspection with acetic acid for cervical-cancer screening: test qualities in a primary-care setting. University of Zimbabwe/JHPIEGO Cervical Cancer Project. Lancet. 1999 Mar 13;353(9156):869-73.</citation>
    <PMID>10093978</PMID>
  </reference>
  <reference>
    <citation>Belinson JL, Pretorius RG, Zhang WH, Wu LY, Qiao YL, Elson P. Cervical cancer screening by simple visual inspection after acetic acid. Obstet Gynecol. 2001 Sep;98(3):441-4.</citation>
    <PMID>11530126</PMID>
  </reference>
  <reference>
    <citation>Denny L, Kuhn L, Pollack A, Wright TC Jr. Direct visual inspection for cervical cancer screening: an analysis of factors influencing test performance. Cancer. 2002 Mar 15;94(6):1699-707.</citation>
    <PMID>11920531</PMID>
  </reference>
  <reference>
    <citation>Sauvaget C, Fayette JM, Muwonge R, Wesley R, Sankaranarayanan R. Accuracy of visual inspection with acetic acid for cervical cancer screening. Int J Gynaecol Obstet. 2011 Apr;113(1):14-24. doi: 10.1016/j.ijgo.2010.10.012. Epub 2011 Jan 22. Review.</citation>
    <PMID>21257169</PMID>
  </reference>
  <reference>
    <citation>Bosgraaf RP, Mast PP, Struik-van der Zanden PH, Bulten J, Massuger LF, Bekkers RL. Overtreatment in a see-and-treat approach to cervical intraepithelial lesions. Obstet Gynecol. 2013 Jun;121(6):1209-16. doi: 10.1097/AOG.0b013e318293ab22.</citation>
    <PMID>23812454</PMID>
  </reference>
  <reference>
    <citation>Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, Schneider A, Lotz B, Melsheimer P, von Knebel Doeberitz M. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res. 1999 Dec 15;59(24):6132-6.</citation>
    <PMID>10626803</PMID>
  </reference>
  <reference>
    <citation>Fiedler M, Müller-Holzner E, Viertler HP, Widschwendter A, Laich A, Pfister G, Spoden GA, Jansen-Dürr P, Zwerschke W. High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies. FASEB J. 2004 Jul;18(10):1120-2. Epub 2004 May 20.</citation>
    <PMID>15155561</PMID>
  </reference>
  <reference>
    <citation>Yang YS, Smith-McCune K, Darragh TM, Lai Y, Lin JH, Chang TC, Guo HY, Kesler T, Carter A, Castle PE, Cheng S. Direct human papillomavirus E6 whole-cell enzyme-linked immunosorbent assay for objective measurement of E6 oncoproteins in cytology samples. Clin Vaccine Immunol. 2012 Sep;19(9):1474-9. doi: 10.1128/CVI.00388-12. Epub 2012 Jul 18.</citation>
    <PMID>22815148</PMID>
  </reference>
  <reference>
    <citation>Schweizer J, Lu PS, Mahoney CW, Berard-Bergery M, Ho M, Ramasamy V, Silver JE, Bisht A, Labiad Y, Peck RB, Lim J, Jeronimo J, Howard R, Gravitt PE, Castle PE. Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer. J Clin Microbiol. 2010 Dec;48(12):4646-8. doi: 10.1128/JCM.01315-10. Epub 2010 Oct 6.</citation>
    <PMID>20926711</PMID>
  </reference>
  <reference>
    <citation>Zhao FH, Jeronimo J, Qiao YL, Schweizer J, Chen W, Valdez M, Lu P, Zhang X, Kang LN, Bansil P, Paul P, Mahoney C, Berard-Bergery M, Bai P, Peck R, Li J, Chen F, Stoler MH, Castle PE. An evaluation of novel, lower-cost molecular screening tests for human papillomavirus in rural China. Cancer Prev Res (Phila). 2013 Sep;6(9):938-48. doi: 10.1158/1940-6207.CAPR-13-0091. Epub 2013 Jul 22.</citation>
    <PMID>23878179</PMID>
  </reference>
  <reference>
    <citation>Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA. HPV screening for cervical cancer in rural India. N Engl J Med. 2009 Apr 2;360(14):1385-94. doi: 10.1056/NEJMoa0808516.</citation>
    <PMID>19339719</PMID>
  </reference>
  <reference>
    <citation>Gravitt PE, Belinson JL, Salmeron J, Shah KV. Looking ahead: a case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy. Int J Cancer. 2011 Aug 1;129(3):517-27. doi: 10.1002/ijc.25974. Review.</citation>
    <PMID>21384341</PMID>
  </reference>
  <reference>
    <citation>Pierce MC, Guan Y, Quinn MK, Zhang X, Zhang WH, Qiao YL, Castle P, Richards-Kortum R. A pilot study of low-cost, high-resolution microendoscopy as a tool for identifying women with cervical precancer. Cancer Prev Res (Phila). 2012 Nov;5(11):1273-9. doi: 10.1158/1940-6207.CAPR-12-0221. Epub 2012 Aug 27.</citation>
    <PMID>22926339</PMID>
  </reference>
  <reference>
    <citation>J. Hintze, PASS 11. NCSS, LLC. Kaysville, Utah, USA, (2011).</citation>
  </reference>
  <reference>
    <citation>Massad LS, Jeronimo J, Katki HA, Schiffman M; National Institutes of Health/American Society for Colposcopy and Cervical Pathology Research Group. The accuracy of colposcopic grading for detection of high-grade cervical intraepithelial neoplasia. J Low Genit Tract Dis. 2009 Jul;13(3):137-44. doi: 10.1097/LGT.0b013e31819308d4.</citation>
    <PMID>19550210</PMID>
  </reference>
  <reference>
    <citation>Pretorius RG, Zhang WH, Belinson JL, Huang MN, Wu LY, Zhang X, Qiao YL. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol. 2004 Aug;191(2):430-4.</citation>
    <PMID>15343217</PMID>
  </reference>
  <reference>
    <citation>Pretorius RG, Belinson JL, Burchette RJ, Hu S, Zhang X, Qiao YL. Regardless of skill, performing more biopsies increases the sensitivity of colposcopy. J Low Genit Tract Dis. 2011 Jul;15(3):180-8. doi: 10.1097/LGT.0b013e3181fb4547.</citation>
    <PMID>21436729</PMID>
  </reference>
  <reference>
    <citation>Pretorius RG, Kim RJ, Belinson JL, Elson P, Qiao YL. Inflation of sensitivity of cervical cancer screening tests secondary to correlated error in colposcopy. J Low Genit Tract Dis. 2006 Jan;10(1):5-9.</citation>
    <PMID>16378026</PMID>
  </reference>
  <reference>
    <citation>Pretorius RG, Bao YP, Belinson JL, Burchette RJ, Smith JS, Qiao YL. Inappropriate gold standard bias in cervical cancer screening studies. Int J Cancer. 2007 Nov 15;121(10):2218-24.</citation>
    <PMID>17657715</PMID>
  </reference>
  <reference>
    <citation>Janssen PA, Selwood BL, Dobson SR, Peacock D, Thiessen PN. To dye or not to dye: a randomized, clinical trial of a triple dye/alcohol regime versus dry cord care. Pediatrics. 2003 Jan;111(1):15-20.</citation>
    <PMID>12509548</PMID>
  </reference>
  <reference>
    <citation>M.TP, L. CW, C. M, S. WW, Trends in Umbilical Cord Care: Scientific Evidence for Practice. Newborn and Infant Nursing Reviews 4, 211 (2004)</citation>
  </reference>
  <reference>
    <citation>Polglase AL, McLaren WJ, Skinner SA, Kiesslich R, Neurath MF, Delaney PM. A fluorescence confocal endomicroscope for in vivo microscopy of the upper- and the lower-GI tract. Gastrointest Endosc. 2005 Nov;62(5):686-95.</citation>
    <PMID>16246680</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 10, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>William Marsh Rice University</investigator_affiliation>
    <investigator_full_name>Rebecca Richards-Kortum</investigator_full_name>
    <investigator_title>Malcolm Gillis University Professor, Professor of Bioengineering</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>REDCap platform will be used to share data.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT04472455/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

